NMD Pharma secures €75M from insiders for three PhII trials in neuromuscular disorders
Danish biotech NMD Pharma, named for its focus on neuromuscular disorders, has tacked on €75 million ($81 million) to bankroll three Phase II studies of its main drug candidate.
The funding will support Phase II trials of its CIC-1 molecule inhibitor NMD670 in patients with spinal muscular atrophy (SMA), myasthenia gravis and Charcot-Marie-Tooth disease, NMD said Wednesday morning.
It also gives NMD another three years of runway, CEO Thomas Holm Pedersen told Endpoints News. The SMA trial will be the first one to read out data, sometime in 2025. The SMA study has already begun, and the other two trials will start next year, he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.